In observational studies, abdominal adiposity has been associated with type 2 diabetes and coronary heart disease (CHD). Whether these associations represent causal relationships remains uncertain.
However, for any given BMI, body fat distribution can vary substantially; some individuals store proportionally more fat around their visceral organs (abdominal adiposity) than on their thighs and hip. 3 Waist-to-hip ratio (WHR) adjusted for BMI is a surrogate measure of abdominal adiposity and has been correlated with direct imaging assessments of abdominal fat. 4, 5 In observational studies, abdominal adiposity has been associated with cardiometabolic disease 6, 7 ; however, whether this association is causal remains unclear. For example, unmeasured lifestyle factors 8 might confound observational studies that link WHR adjusted for BMI with type 2 diabetes and CHD. Furthermore, reverse causality could similarly lead to a statistically robust but noncausal relationship. For example, individuals with subclinical CHD might develop abdominal adiposity because of an inability to exercise. Mendelian randomization is a human genetics tool that leverages the random assortment of genetic variants at time of conception to facilitate causal inference. 9 Because genetic predisposition to abdominal adiposity is determined by DNA sequence variants, it is less likely to be affected by confounding or reverse causality. In this study, a mendelian randomization approach was used to determine whether a genetic predisposition to increased WHR adjusted for BMI is associated with cardiometabolic quantitative traits, type 2 diabetes, and CHD.
Methods

Study Design and Instruments
Observational epidemiology studies test association of an exposure (eg, WHR adjusted for BMI) with an outcome (eg, CHD). However, unobserved confounders may affect both exposure and outcome, thus biasing the observed association ( Figure 1 ; eMethods A in the Supplement). Because genetic variants are both randomly assorted in a population and assigned at conception, they are largely unassociated with confounders and can be used as instrumental variables to estimate the causal association of an exposure (WHR adjusted for BMI) with an outcome. 9 This mendelian randomization approach has 3 assumptions. 10 First, genetic variants used as an instrument must be associated with the exposure of interest (eg, WHR adjusted for BMI) (assumption 1 in Figure 1 ). Second, genetic variants must not be associated with confounders (assumption 2 in Figure 1 ). Third, genetic variants must not be associated with outcome independently of the exposure (assumption 3 in Figure 1 ). The second and third assumptions are collectively known as independence from pleiotropy. Mendelian randomization can be extended to conduct a mediation analysis, estimating the proportion of an observed association of an exposure (WHR adjusted for BMI) with an outcome (CHD) that occurs through a given mediator ( Figure 1 ). A mendelian randomization study using publicly available, summary-level data from large-scale genome-wide association studies (GWASs) (both cross-sectional and case-control data sets) as well as individual-level data from the UK Biobank (a cross-sectional data set) was conducted ( Figure 2) . [12] [13] [14] [15] [16] [17] [18] The primary instrument was a polygenic risk score for WHR adjusted for BMI. A recent large-scale GWAS from the Genome-Wide Investigation of Anthropometric Traits (GIANT) Consortium identified 48 single-nucleotide polymorphisms (SNPs), or genetic variants, associated with WHR adjusted for BMI (eTable 1 in the Supplement). 14 Combining these 48 SNPs into a weighted polygenic risk score enabled quantification of the genetic predisposition to increased WHR adjusted for BMI for each individual.
Data Sources and Study Participants
Summary-level data from 6 GWAS consortia were used (GWASs conducted from 2007 to 2015) (eTable 3; eMethods B in the Supplement). [12] [13] [14] [15] [16] [17] [18] For WHR, BMI, waist circumference, hip circumference, and WHR adjusted for BMI, data from the GIANT Consortium was used (GWASs conducted from 2007 to 2013) 14, 15 ; this study included 322 154 individuals of European descent for BMI and 210 088 individuals of European descent for waist circumference, hip circumference, WHR, and WHR adjusted for BMI. The results from 5 additional GWAS (conducted from 2007 to 2015) examining blood lipids, glycemic traits, renal function, type 2 diabetes, and CHD, and predominantly including individuals of European descent, were also assessed. 11, 13, 16, 17, 19, 20 ), respectively. Informed consent was obtained from all participants of contributing studies. Contributing studies received ethical approval from their respective institutional review boards.
Individual-level data from 111 986 individuals of European ancestry from the UK Biobank, collected from 2007 to 2011, were also used (Table; eMethods C in the Supplement). The UK Biobank received ethical approval from the research ethics committee (reference number 11/NW/0382). Analysis of the UK Biobank data was approved by the Partners Health Care institutional review board (protocol 2013P001840). Informed consent was obtained from all participants by the UK Biobank.
Type 2 diabetes and CHD were both ascertained at baseline by self-report, followed by a verbal interview with a trained nurse to confirm the diagnosis (eTable 4 in the Supplement). Type 2 diabetes was defined as report of type 2 diabetes, report of type 2 diabetes unspecified, or current use of insulin medication. CHD was defined as report of previous myocardial infarction or diagnosis of angina or hospitalization for myocardial infarction (International Statistical Classification of Diseases and Related Health Problems, Tenth Revision codes I21-I23).
In addition to the primary outcomes of type 2 diabetes and CHD, a phenome-wide association study (an analysis of the association of a genetic variant or polygenic risk score with a broad range of diseases, outcomes, or both) for 35 additional diseases, including endocrine, renal, urologic, gastrointestinal, neurologic, musculoskeletal, respiratory, and cancer disorders, was conducted in the UK Biobank to attempt to iden-
Figure 1. Assumptions of a Mendelian Randomization Analysis
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Genetic variants, which are assigned at birth and largely randomly assorted in a population, can be used as instrumental variables to estimate the causal association of an exposure (eg, waist-to-hip ratio [WHR] adjusted for body mass index [BMI] ) with an outcome of interest (eg, coronary heart disease). This approach rests on 3 assumptions. First, the genetic variants must be associated with the exposure (assumption 1). Second, the genetic variants must not be associated with confounders (assumption 2). Third, the genetic variants must influence risk of the outcome through the exposure and not through other pathways (assumption 3). Mendelian randomization can be extended to estimate the association of exposure with outcome that is mediated by a given a mediator (eg, triglycerides). A polygenic score of 48 single-nucleotide polymorphisms was used as an instrument to estimate the causal association of waist-to-hip ratio (WHR) adjusted for body mass index (BMI) with cardiometabolic quantitative traits, type 2 diabetes, and coronary heart disease; sources of data for analysis included the UK Biobank and publicly available genome-wide association studies. CARDIOGRAMplusC4D indicates Coronary Artery DIsease Genome-wide Replication and Meta-analysis plus the Coronary Artery Disease Genetics Consortium
Figure 2. Study Design
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; CKDGen, Chronic Kidney Disease Genetics Consortium 12 ; DIAGRAM, Diabetes Genetics Replication and Meta-analysis 13 ; GIANT, Genetic Investigation of Anthropometric Traits tify whether the polygenic risk score for WHR adjusted for BMI is associated with any additional disorders (eTable 4 in the Supplement).
Statistical Analysis
For analyses of both summary-level data and UK Biobank data, a weighted polygenic risk score was derived based on the magnitude of association of each SNP with WHR adjusted for BMI in the previously published GIANT analysis. 19 The association of polygenic risk score with each continuous trait and dichotomous outcome was then calculated after standardization to a 1-SD predicted change in WHR adjusted for BMI.
For the summary-level data, this approach is equivalent to an inverse-variance-weighted fixed-effects meta-analysis of the association of each SNP with the trait or outcome of interest (eg, CHD), divided by the association of each SNP with WHR adjusted for BMI. 21 Explicitly, if x is the association of each SNP with the outcome of interest, and w the association of each SNP with WHR adjusted for BMI, then the estimated genetic association of WHR adjusted for BMI with the outcome was calculated as a fixed-effects meta-analysis of
x/w for all SNPs.
To validate that the polygenic risk score for WHR adjusted for BMI was a strong instrument for WHR adjusted for BMI (assumption 1 in Figure 1 ), an F statistic for the instrument was calculated in the UK Biobank. An F statistic is a measure of the significance of an instrument (the polygenic risk score) for prediction of the exposure (WHR adjusted for BMI), controlling for additional covariates (age, sex, 10 principal components of ancestry, and a dummy variable for the array type used in genotyping). An F statistic greater than 10 is evidence of a strong instrument. 22 For individual-level data from the UK Biobank, logistic regression was used to determine association of a polygenic risk score for WHR adjusted for BMI and dichotomous outcomes (type 2 diabetes, CHD, and 35 additional diseases) (eMethods CintheSupplement). 23 Linear regression was used for continuous traits (anthropometric traits and blood pressure) in the UK Biobank. All UK Biobank analyses included adjustment for age, sex, 10 principal components of ancestry, and a dummy variable for the array type used in genotyping. The inclusion of principal components of ancestry as covariates is commonly implemented to correct for population stratification according to ancestral background. 24 To test assumption 2 (independence of polygenic risk score for WHR adjusted for BMI from potential confounders) (Figure 1) , the relationship of the polygenic risk score to smoking, alcohol use, physical activity, vegetable consumption, red meat consumption, and breastfeeding status as a child was determined among individuals in the UK Biobank. Test for trend was performed across quartiles of the polygenic risk score for WHR adjusted for BMI using logistic regression, with each potential confounder as the outcome. For comparison, individuals in the UK Biobank were stratified into quartiles by observational WHR adjusted for BMI and test for trend performed using logistic regression.
Five additional sensitivity analyses were conducted to test the robustness of the results (eMethods D in the Supplement).
Three additional polygenic risk scores were used, including one that included variants not significantly associated with BMI, a second that included variants significantly associated with gene expression in adipose tissue, and a third that included variants significantly associated with increased WHR adjusted for BMI in women but not in men. The association of genetic variants with BMI was adjusted for, and median regression was used (eMethods D in the Supplement). 10 The rationale for these sensitivity analyses is provided in eMethods D. Absolute increases associated with WHR adjusted for BMI for type 2 diabetes and CHD were calculated using the United States population incidence of type 2 diabetes and CHD (eMethods E in the Supplement). Tests for nonlinear associations of a genetic predisposition to increased WHR adjusted for BMI with type 2 diabetes and CHD were performed using nonlinear instrumental variable estimation (eMethods F in the Supplement). 25 The threshold of statistical significance for type 2 diabetes and CHD (main outcome measures) was P < .025 (.05/2 = .025). The threshold of significance for the analysis of 15 traits was P < .0033 (.05/15 = .0033). The threshold of significance in the phenome-wide association analysis was P < .0014 (.05/35 = .0014).
Mediation Analysis
Among continuous traits, the polygenic risk score for WHR adjusted for BMI was most strongly associated with plasma triglyceride levels. The extent to which the polygenic risk score association with CHD was mediated by plasma triglycerides was tested using mediation analysis, conducted post hoc after triglyceride level was identified as the cardiometabolic trait most strongly associated with WHR adjusted for BMI. BMI polygenic risk score with triglyceride level (estimated using linear regression). To derive the remaining proportion of CHD risk unaccounted for by an increase in triglyceride levels, the magnitude of association of the change in triglyceride level with CHD was subtracted from the estimate of the genetic association of WHR adjusted for BMI with CHD (estimated using logistic regression). Analyses were performed using R version 3.2.3 (R Project for Statistical Computing) and Stata version 12 (StataCorp).
Results
The characteristics of UK Biobank participants are reported in the Table. The mean age was 56.9 (SD, 7.9) years, mean systolic blood pressure was 143.6 mm Hg (SD, 21.8), and mean diastolic blood pressure was 84.5 mm Hg (SD, 11.8); 5639 participants (5.0%) had CHD, and 5690 (5.1%) had type 2 diabetes.
A 48-SNP polygenic risk score for WHR adjusted for BMI was a strong instrumental variable (F = 1713), statistically accounting for 1.5% of variance in WHR adjusted for BMI in the UK Biobank, thus validating assumption 1 in Figure 1 .
To test assumption 2 (independence of polygenic risk score for WHR adjusted for BMI from potential confounders, Figure 1 ), the relationship of the polygenic risk score to smoking, alcohol use, physical activity, vegetable consumption, red meat consumption, and breastfeeding status as a child was determined among individuals in the UK Biobank. In each case, no significant relationship was noted (eTable 5 in the Supplement). For comparison, a similar analysis that categorized individuals according to observed WHR adjusted for BMI (instead of genetic predisposition to WHR adjusted for BMI) was conducted (eTable 6 in the Supplement). In this observational epidemiology analysis, WHR adjusted for BMI was associated with each potential confounder.
A 1-SD increase in WHR adjusted for BMI due to the polygenic risk score was associated with a 1-point decrease in BMI (95% CI, 0.87-1.1), a 2-cm increase in waist circumference (95% CI, 1.5-2.4), a 4.1-cm decrease in hip circumference (95% CI, 3.8-4.4), and an increase of 0.068 in WHR (95% CI, 0.066-0.070) ( Figure 3 14, 15 ) were pooled with data from the UK Biobank (derived instrumental variables regression adjusting for age, sex, 10 principal components of ancestry, and array type) using inverse variance-weighted fixed-effects meta-analysis. For lipids, glycemic, and renal function traits, estimates were derived from genome-wide association studies (Global Lipids Genetics, 16 Meta-analyses of Glucose and Insulin-Related Traits, 17 and Chronic Kidney Genetics Consortia, 12 respectively).
For blood pressure, estimates were derived from UK Biobank. Two-hour glucose refers to measured blood glucose levels 2 hours after consumption of dissolved glucose. ; number of participants with CHD outcome, 66 440) ( Figure 4 ).
Five sensitivity analyses (eMethods D, eFigures 1-9 in the Supplement) of the genetic association of WHR adjusted for BMI with cardiometabolic traits, type 2 diabetes, and CHD were conducted to examine if results were influenced by pleiotropy (ie, a violation of assumptions 2 or 3 in Figure 1 ). Four of the 5 sensitivity analyses were consistent with the results not being influenced by pleiotropy (eFigures 1-7 in the Supplement). In the fifth sensitivity analysis, 8 SNPs associated with increased WHR adjusted for BMI in women but not men were combined in an additive risk score. If increased WHR adjusted for BMI causes CHD (rather than results being due to pleiotropy), then a risk score that increases WHR adjusted for BMI in women but not in men should increase risk of CHD in women but not in men. Although a numerically greater magnitude of association with type 2 diabetes and CHD was noted in women as compared with men, no significant difference was observed (P = 0.10 and P = 0.11, respectively, for interaction) (eFigures 8 and 9, eMethods D in the Supplement).
Using the polygenic risk score of 48 SNPs associated with WHR adjusted for BMI, a phenome-wide association study of 35 additional diseases in the UK Biobank was conducted ( Figure 5 ). There was no significant association of WHR adjusted for BMI with any of these diseases at the Bonferroniadjusted level of significance (P < .0014).
In mediation analysis, the association of polygenic risk score for WHR adjusted for BMI with CHD was attenuated from an OR of 1.46 (95% CI, 1.32-1.62) to an OR of 1.23 (95% CI, 1.11-1.36), after accounting for the association of the polygenic risk score with triglyceride level (eFigure 10 in the Supplement).
Discussion
Mendelian randomization analyses tested if human genetic evidence supported a causal relationship of WHR adjusted for BMI (a measure of abdominal adiposity) with type 2 diabetes and CHD. Genetic predisposition to higher WHR adjusted for BMI was associated with increased levels of quantitative risk factors (lipids, insulin, glucose, and systolic blood pressure) as well as a higher risk for type 2 diabetes (OR, 1.77 [95% CI, 1.57-2.00] per 1-SD higher WHR adjusted for BMI) and CHD (OR, 1.46 [95% CI, 1.32-1.62] per 1-SD higher WHR adjusted for BMI).
These results permit several conclusions. First, these findings lend human genetic support to previous observations associating abdominal adiposity with cardiometabolic disease. 6, 7 In the INTERHEART acute myocardial infarction casecontrol study, a 1-SD higher WHR was associated with increased odds of myocardial infarction (OR, 1.37 [95% CI, 1.33-1.40]) after adjustment for BMI and other covariates. 6 However, residual confounding or reverse causality may have contributed to these associations. Indeed, in this study, observational WHR adjusted for BMI was strongly associated with potential confounders, illustrating a limitation of observational Results are standardized to a 1-SD increase in waist-to-hip ratio adjusted for body mass index due to polygenic risk score. Estimates were independently derived in genome-wide association studies (CARDIOGRAMplusC4D for coronary heart disease and DIAGRAM for type 2 diabetes) and the UK Biobank. The threshold of significance was P < .025 (0.05/2 = 0.025). Size of data markers is inversely proportional to variance of estimate. epidemiology. Here, these prior findings were extended by testing a polygenic risk score that appeared independent of measured confounders (eTable 5 in the Supplement). Elevated levels of triglyceride-rich lipoproteins, a risk factor for CHD with genetic and experimental evidence for causality, 26,27 appeared to mediate a substantial proportion of the increased risk for CHD. Second, these results suggest that body fat distribution, beyond simple measurement of BMI, could explain part of the variation in risk of type 2 diabetes and CHD noted across individuals and subpopulations. For example, increased abdominal adiposity at a given BMI has been proposed as an explanation for the excess risk of CHD observed in South Asians. 28 Similarly, greater abdominal adipose tissue at a given BMI has been proposed to underlie the excess risk of CHD at a given BMI among men compared with women. 29 In the INTERHEART study, which observed a similar strength of association of WHR adjusted for BMI with myocardial infarc- Results are standardized to a 1-SD increase in waist-to-hip ratio adjusted for body mass index due to polygenic risk score. All estimates were derived in UK Biobank using instrumental variables regression (adjusting for age, sex, and 10 principal components of ancestry). The threshold for significance was P < .0014 (0.05/35 = 0.0014). Size of data markers is inversely proportional to variance of estimate. COPD indicates chronic obstructive pulmonary disease; OR, odds ratio; SNP, single-nucleotide polymorphism. tion as the genetic estimate reported here, 33.7% of myocardial infarctions were attributed to increased WHR compared with 10.8% of infarctions attributed to overweight and obesity (BMI >25). 6 When combined with the evidence supportive of causality reported here, these results raise the potential that abdominal adiposity, independent of elevated BMI, is a major driver of global CHD burden. Third, WHR adjusted for BMI might prove useful as a biomarker for the development of therapies to prevent type 2 diabetes and CHD. Although a substantial focus of drug development has been toward therapeutics to reduce overall adiposity, 30 there has been little effort toward the development of therapies that modify body fat distribution to reduce abdominal adiposity. Ongoing research to understand the mechanistic links between the numerous genetic loci that influence WHR adjusted for BMI may lead to novel therapeutic strategies to reduce abdominal adiposity and reduce the risk of type 2 diabetes and CHD. The mendelian randomization approach used in this study rests on 2 major principles ( Figure 1 ). First, it requires a strong link between the genetic variants used as an instrument and the exposure (WHR adjusted for BMI, assumption 1 in Figure 1 ). The 48-SNP polygenic risk score explained 1.5% of variance in WHR adjusted for BMI and had an F statistic of 1713 in the UK Biobank, classifying it as a strong instrument with negligible weak instrument bias. 31 Second, mendelian randomization assumes the absence of pleiotropy, that is, it assumes that the genetic variants used as an instrument affect the outcome (CHD) through the exposure (WHR adjusted for BMI) and not through any other pathway or confounding factors (assumptions 2 and 3 in Figure 1 ). Although it is not possible to directly test whether pleiotropy is present in any mendelian randomization study, 32 a number of steps were taken in this study to reduce the risk of pleiotropy, including use of 3 different genetic instruments, use of weighted median regression, and use of an instrument associated with higher WHR adjusted for BMI in women but not men. Results from 4 of 5 of these sensitivity analyses were consistent with the primary results. Tests for interaction using sex-specific instruments for CHD and diabetes were directionally consistent with expectation but did not demonstrate significant heterogeneity of effect by sex. This analysis required individual-level data available only in UK Biobank participants and may have been underpowered to detect a difference. Future research that explores such sex-specific instruments in larger data sets may prove more conclusive. This study has several limitations. First, although a number of approaches were used in an attempt to rule out pleiotropy, it is possible that these results represent a shared genetic basis between WHR adjusted for BMI and CHD rather than a causal relationship. Second, prevalent events largely derived from a verbal interview with a nurse were used for the phenome-wide association study of 35 different disorders. Although these events are likely to be of greater specificity and sensitivity than coded mortality data, they have not been independently validated. Third, the phenome-wide association study may have been underpowered to detect an association of genetic WHR adjusted for BMI with outcomes other than type 2 diabetes and CHD. Fourth, this analysis was restricted to individuals of European ancestry; the association of genetic WHR adjusted for BMI with type 2 diabetes and CHD may differ by ethnicity or genetic ancestry.
Conclusions
A genetic predisposition to higher WHR adjusted for BMI was associated with increased risk of type 2 diabetes and CHD. These results provide evidence supportive of a causal association between abdominal adiposity and these outcomes.
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A. Principles of Mendelian randomization
Traditional observational epidemiology attempts to measure an association between an exposure (e.g. WHRadjBMI) and an outcome (e.g. coronary heart disease), while adjusting for potential confounders (e.g. age, sex, education). Assuming that all potential confounders are appropriately adjusted for, this approach can derive a causal association of WHRadjBMI with the outcome of interest. In practice, however, many confounders are unobserved or unmeasured and thus cannot be adjusted for. Furthermore, presence of the outcome at baseline, if unobserved, may affect the exposure. For example, undiagnosed coronary heart disease at baseline may lower measured blood pressure. As a result of confounding and reverse causality, observational studies may lead to estimated associations discrepant from their true values.
Mendelian randomization is based on the premise that genetic variants are distributed largely at random in the population. As a result, genetic variants are typically not associated with the traditional confounders (education, income, healthy living etc.) that may bias observational studies. 1 Consequently, if there is a causal relationship between the exposure and outcome of interest, a genetic variant or collection of variants that increases levels of the exposure should be associated with the outcome. If, on the other hand, an observational association between an exposure and an outcome is due to confounding, a genetic variant that increases levels of the exposure should be unassociated with the outcome.
The major limitation of Mendelian randomization is pleiotropy. If a genetic variant used as an instrument for an exposure affects risk of the outcome through a pathway independent of the exposure, estimates derived from Mendelian randomization will be biased. 1 Risk of pleiotropy should thus be minimized through sensitivity analyses and through careful selection of genetic variants. 1 Nonetheless, Mendelian randomization is a powerful approach to test if the association of an exposure with outcome seen in observational epidemiology represents a causal relationship.
B. Summary level data from genome-wide association studies
Data
An overview of the included genome-wide association studies (GWAS) is provided in eTable 3.
For waist-to-hip ratio adjusted for body mass index, waist-to-hip ratio, body mass index, waist circumference and hip circumference, data from the Genetic Investigation of ANthropometric Traits (GIANT) consortium was used. 2, 3 For waist-to-hip ratio, waist circumference and hip circumference, data from 210,088 individuals of European ancestry were included. For body mass index, data for 322,154 individuals of European ancestry were included. Individuals were genotyped using various arrays and imputed with the HapMap reference panel to 2.5 million single nucleotide polymorphisms (SNPs).
For lipids (total cholesterol, LDL cholesterol, HDL cholesterol, and triglycerides), data from the Global Lipids Genetic Consortium, a meta-analysis of 188,577 individuals of European descent, was used. 4 This GWAS included 37 studies genotyped using the Illumina Metabochip array as well as an additional 23 studies genotyped using a variety of arrays.
For glycemic traits, data from the Meta-Analyses of Glucose and Insulin-related traits Consortium (MAGIC), which included 133,010 individuals of European ancestry without diabetes, was used. 5 This consortium included studies genotyped using the Metabochip as well as studies genotyped using various arrays with imputation to 2.5 million SNPs using the HapMap reference panel. SNPs included on the Metabochip were then meta-analyzed across studies.
For estimated glomerular filtration rate (eGFR) and chronic kidney disease, data from the Chronic Kidney Disease Genetics consortium (CKDGen), a meta-analysis of 133,413 individuals of European descent from 49 studies, was used. 6 Individuals were genotyped using various arrays and imputed with the HapMap reference panel to 2.5 million SNPs.
For coronary heart disease, data from the 1000 Genomes Imputation of CARDIOGRAMplusC4D was used. This study was a meta-analysis of up to 184,305 individuals (60,801 coronary heart disease (CHD) cases and 123,504 controls), the majority (77%) of whom were of European ancestry with remain individuals predominantly of South Asian (13%) and East Asian descent (6%). 7 Remaining individuals were of African-American and Hispanic ancestry. This meta-analysis included 48 studies genotyped using the Illumina Metabochip array and imputed to 38 million variants using 1000 Genomes data. One SNP associated with WHRadjBMI (rs7759742) was not available in CARDIOGRAMplusC4D 1000 Genomes imputation, but was available in an earlier CARDIOGRAMplusC4d consortium; 8 the estimate from CARDIOGRAMplusC4D was thus used for this SNP.
For diabetes, data from the DIAbetes Genetics Replication and Meta-analysis (DIAGRAM) Consortium was used. This study was a meta-analysis of 34 840 diabetes cases and 114 981 controls, overwhelmingly of European descent. 9 This meta-analysis included 12 studies genotyped using a range of arrays and imputed with the HapMap reference panel to 2.5 million SNPs. These studies were meta-analysed with 26 studies genotyped using the Illumina Metabochip array.
Standardization of Cardiometabolic Trait Estimates
While GIANT and GLGC reported estimates of variants in units of standard deviations, the MAGIC and CKDGen consortia did not. Betas from these two consortia were standardized so that the association of WHRadjBMI with cardiometabolic traits could be uniformly expressed in terms of standard deviations. For HbA1c, fasting glucose and two-hour glucose from the MAGIC consortium, one standard deviation (SD) was assumed to correspond to 0.535%, 13.1 mg/dl and 10.1 mg/dl, the pooled standard deviation of studies included in a previous report from the MAGIC consortium. 10 As a pooled standard deviation for log-transformed fasting insulin was not available from the MAGIC consortium, an estimate of 0.44 from the Framingham Offspring Study was used. 11 For CKDGen, to express estimated glomerular filtration rate in absolute terms, a published estimate from white individuals in the National Health and Nutrition Examination Survey (NHANES) was used, assuming that one SD in eGFR corresponds to 49.1 mL/min. 12 To express increases in lipid levels in absolute terms, which may be easier for clinicians to interpret, population level standard deviations in lipid levels using NHANES survey data from 2005-2012 were calculated. A one SD in total cholesterol was 39.8 mg/dl, a one SD in LDL cholesterol was 34.8 mg/dl, a one SD in HDL cholesterol was 15.5 mg/dl and a one SD in triglycerides was 65.6 mg/dl. To express BMI, WHR, waist circumference and hip circumference in absolute terms, standard deviation estimates from UK Biobank were used. One SD in BMI, WHR, waist circumference and hip circumference corresponded to 4.8 kg/m2, 0.09, 13.6 cm and 9.2 cm, respectively.
C. Individual level data from UK Biobank and derivation of polygenic risk scores Data
Individual level genetic data was available from 111,986 individuals in UK Biobank, after excluding related samples, individuals whose genetic sex did not match self-reported sex and extreme outliers. Of these individuals, 38,505 were genotyped using the Affymetrix UK BiLEVE array and 73,481 individuals were genotyped using the Affymetrix UK Biobank Axiom Array. Phasing and imputation were performed centrally, by UK Biobank, using a reference panel combining UK10k and 1000 Genomes samples. 73,355,667 variants were imputed.
To adjust for the presence of antihypertensive medication, 15 mm Hg was added to systolic blood pressure and 10 mm Hg was added to diastolic blood pressure of individuals on antihypertensive medication at baseline. This addition has been applied in previous genome-wide association studies 13 and suggested in a simulation study to produce accurate estimates of model parameters.
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Polygenic risk scores
To derive polygenic risk scores for use in UK Biobank, the number of risk alleles for each individual was multiplied by the reported association of each SNP with waist-to-hip ratio adjusted for body mass index (WHRadjBMI) from the GIANT consortium (eTable 1). 2 One SNP (rs1534696) that was associated with WHRadjBMI in an all-ancestry analysis in GIANT, but not in a European ancestry specific analysis, was excluded, as Mendelian randomization rests on the assumption that genetic variants used as instruments are associated with the exposure of interest (WHRadjBMI), and rs1534696 is not significantly associated with WHRadjBMI in populations of European ancestry (the populations predominantly analysed). All 48 remaining SNPs that were associated with WHRadjBMI in GIANT (in either sex-specific or sexcombined analyses) were included in the primary score (All SNPs). 24 SNPs that were not associated with BMI were used in the non-BMI associated score. 8 SNPs that were linked to gene expression in adipose tissue (that is, associated with eQTLs in adipose tissue 2 ) were used in the adipose-tissue score.
Analysis
For individual level data from UK Biobank, these polygenic risk scores were used to perform an instrumental variable analysis of the association of WHRadjBMI (per SD) with traits and outcomes. For binary outcomes (diabetes, coronary heart disease and 35 additional diseases) iterative reweighted least squares (a maximum quasi-likelihood estimation) logistic regression was used for the instrumental variables regression, adjusting for age, sex, ten principal components of ancestry and a dummy variable for the array type used in genotyping. For continuous outcomes (anthropometric traits and blood pressure), two-stage least squares linear regression was used for the instrumental variables regression, adjusting for age, sex, ten principal components of ancestry and a dummy variable for the array type used in genotyping.
D. Sensitivity analyses
Five additional sensitivity analyses were conducted to examine the robustness of the results. Second, an instrument restricted to 8 SNPs associated with WHRadjBMI that are known to regulate gene expression in adipose tissue was used. 2 Unlike the 48 SNP primary score and 24 SNP secondary score, this score is composed of variants known to be associated with expression of the relevant gene in adipose tissue. If WHRadjBMI causes type 2 diabetes and CHD, this score with a biological link in adipose tissue should also be associated with risk of type 2 diabetes and CHD. A one SD increase in WHRadjBMI using this polygenic risk score of 8 SNPs which modify gene expression in adipose tissue was also associated with elevated triglycerides (44 CI 37, 51 mg/dl; p=1.0*10 -32 ), type 2 diabetes (OR 2.23 CI 1.62, 3.06; p=7.8*10 -7 ) and coronary heart disease (OR 1.74 CI 1.32, 2.30; p=8.87*10 -5 ; eFigures 1-3).
Third, the association of SNPs with body mass index based on summary-level data and measured BMI in UK Biobank were included as additional covariates to examine whether residual confounding by BMI was influencing the results. A one SD increase in WHRadjBMI using the primary polygenic risk score remained associated with type 2 diabetes and CHD after additional adjustment for the associations of variants with BMI (eFigures 4-6).
Fourth, weighted median regression, which has been shown to derive consistent estimates when up to half of instruments are not valid, was used as an additional sensitivity analysis to examine if estimates were biased by unobserved pleiotropy. 15 A one SD increase in WHRadjBMI using the primary 48 SNP polygenic risk score was associated with type 2 diabetes (OR 1.54 CI 1.24, 1.92; p=1.2*10 -4 ) and CHD (OR 1.39 CI 1.18, 1.65; p=1.2*10 -4 ) in an analysis using this approach (eFigure 7).
Fifth, a technique applied in the econometrics and Mendelian randomization literature was used (termed a falsification test 16, 17 ) to examine if pleiotropy was influencing our results by exploiting sex differences in the association of certain SNPs with WHRadjBMI. Rather than using genetic variants that are uniformly associated with WHRadjBMI, a polygenic risk score composed of eight SNPs associated with WHRadjBMI only in women was used (eTable 2). 18 This approach protects against pleiotropy influencing the results. 17 If the association of a polygenic risk score associated with WHRadjBMI on CHD is due to pleiotropy (that is, the genetic variants cause CHD through a pathway independent of WHRadjBMI), then the risk score should increase risk of CHD in both women and men. If, on the other hand, WHRadjBMI causes CHD, then a risk score that increases WHRadjBMI in women but not in men should increase risk of CHD in women but not in men.
To derive sex-specific polygenic risk scores, 21 SNPs that were recently identified in the GIANT consortium as associated with higher WHRadjBMI in women, but unassociated with men, were used. 18 SNPs in loci suggested to be involved in the pathogenesis of heart disease (rs9687846 in the MAP3K1 loci 19 ) and diabetes (rs17819328 in the PPARG loci 20 ) were excluded. The remaining 19 SNPs were then tested for association of WHRadjBMI in women and men in UK Biobank. 11 SNPs were either not associated with WHRadjBMI in women in UK Biobank or were associated with WHRadjBMI in men; these were excluded. A polygenic risk score of the remaining 8 SNPs that were associated with higher WHRadjBMI in women but were unassociated with WHRadjBMI in men was then used. This score was used as an instrument to examine the association of a genetically elevated increased WHRadjBMI in women but not men with coronary heart disease and type 2 diabetes in women and men separately (eTable 2). As a sensitivity analysis, the analysis was conducted using all 21 SNPs.
The per allele associations of this risk score with CHD and type 2 diabetes in women and men in UK Biobank were calculated (specified by including an interaction term between the risk score and sex in the model). Tests for interactions between the association of this risk score in women compared to men were performed.
This instrument was associated with WHRadjBMI in women but not men (p interaction = 3.4*10 -37 , eFigure 8). Tests for interaction on the association of this instrument with diabetes and CHD between women and men were nonsignificant (p interaction = 0.1 and 0.11, respectively). However, this instrument was associated with a non-significantly greater risk of type 2 diabetes in women (OR 1.04 CI 1.01, 1.06 per allele) than men (OR 1.01 CI 0.99, 1.03 per allele). This instrument was also associated with a nonsignificantly greater risk of CHD in women (OR 1.03 CI 1.00, 1.06) than men (OR 1.00 CI 0.98, 1.02). When all 21 SNPs previously identified as being associated with WHRadjBMI in women but not men were used in a sensitivity analysis, this instrument increased WHRadjBMI in both women and men (eFigure 9). Tests for interaction by sex for diabetes and CHD were non-significant using this instrument (p= 0.19 and 0.07, respectively), although this instrument was also associated with a numerically greater increase in risk of CHD and diabetes in women than men.
E. Derivation of absolute risk increases
To estimate the absolute risk increases based on calculated odds ratio associated with genetically elevated WHRadjBMI for type 2 diabetes, the United States population level estimate of the incidence of type 2 diabetes by the Center for Disease Control and Prevention was used (7.8/1000 participant years of follow up). 21 To estimate the absolute risk increases associated with WHRadjBMI for coronary heart disease, the American Heart Association estimate of the incidence of coronary heart disease (coronary heart disease death or non-fatal myocardial infarction) in the United States was used (3.9 per 1000 participant years). 22 The absolute risk increase associated with each disease was then calculated using this formula: ARI = (OR-1)*AI where ARI is the absolute risk increase, OR is the odds ratio and AI is the absolute incidence in events per 1000 participant years.
F. Non-linear instrumental variables estimation
The presence of a non-linear relationship between genetic WHRadjBMI and CHD and type 2 diabetes was tested using non-linear instrumental variables estimation. 23 Participants in UK Biobank were stratified into quintiles using the residual of WHRadjBMI conditional on the 48 SNP WHRadjBMI polygenic risk score, as in Burgess et al. 23 That is, participants were stratified into quintiles not by their baseline WHRadjBMI, but by their WHRadjBMI after subtracting the effect of their polygenic risk score on WHRadjBMI. Instrumental variables regression was then performed within quintiles to estimate the association of genetic WHRadjBMI with CHD and type 2 diabetes within quintiles. Tests for linear trend and tests for heterogeneity between quintiles were performed to test for the presence of non-linear associations.
The impact of the polygenic risk score for WHRadjBMI on risk of type 2 diabetes was consistent across the range of observed WHRadjBMI, without evidence of a linear trend or heterogeneity (eTable 7). However, for CHD, the impact of the polygenic risk score was most pronounced among those with the lowest observed WHRadjBMI (P for linear trend = 0.03). A one standard deviation genetic increase in WHRadjBMI was associated with a greater increase in the risk of CHD in the lowest quintile of baseline WHRadjBMI (OR 2.20 CI 1.31, 3.68) than the top quintile of baseline WHRadjBMI (1.26 CI 0.76, 2.09; eTable 7).
G. Presence of collider bias in WHRadjBMI phenotype
Collider bias can occur in genome-wide association studies of phenotypes that are the ratio of two phenotypes and refers to the unexpected inverse association of genetic variants with the phenotype that is the denominator of the ratio. 24 For example, in this study, the association of variants with WHRadjBMI could be because they are associated with elevated waist-to-hip ratio (the expected association) or reduced body mass index (bias). However, all of the 48 variants used that were associated with WHRadjBMI were also associated (p<0.01) with unadjusted WHR (eTable 8) in their respective sex-combined or sex-specific analysis. Furthermore, an analysis in which variants that were significantly associated with body mass index (the denominator of the ratio) was conducted. Estimates using this 24 SNP score are consistent, indicating that our results are not due to our polygenic risk score being inversely associated with body mass index.
H. Replication of asthma association in phenome wide association study
In an attempt to replicate the association of genetic WHRadjBMI with asthma observed in the phenome wide association study in UK Biobank, summary-level data from the "A Multidisciplinary Study to Identify the Genetic and Environmental Causes of Asthma in the European Community" (GABRIEL) consortium of 10365 asthma cases and 16110 controls of European descent was used. 25 This meta-analysis included 23 studies genotyped using an Illumina Human610 quad array. As with other outcomes, an inverse variance weighted fixed effects meta-analysis of the association of each SNP with asthma, divided by the association of each SNP with WHRadjBMI, was conducted.
The nominal association of WHRadjBMI observed with asthma in the UK Biobank phenome wide association study (OR 1.17 CI 1.01, 1.35; p=0.037; Figure 5 ) was not replicated in an independent Mendelian randomization analysis using data from the GABRIEL consortium (eFigure 11). eTable 7. Association of genetically-elevated waist-to-hip ratio adjusted for body mass index (one standard deviation increase) with type 2 diabetes and coronary heart disease, overall and by quintile of WHRadjBMI. Estimates were derived in UK Biobank, using instrumental variables regression adjusting for age, sex, ten principal components of ancestry and array type. Quintiles were derived as in Burgess et al. 23 using the residual of WHRadjBMI conditional on the 48 SNP WHRadjBMI polygenic risk score. That is, quintiles were formed after subtracting the genetic increase in waist-to-hip ratio adjusted for body mass index from the observed waist-to-hip ratio adjusted for body mass index for each participant in UK Biobank. Test for linear trend was performed using inverse variance weighted linear regression and test for heterogeneity using Cochran's Q test. A genome-wide threshold of p<5*10 -8 was used for identification of variants which increased WHRadjBMI in sexcombined or sex-specific analyses. eFigure 1. Association of genetic waist-to-hip ratio adjusted for body mass index with cardiometabolic traits using three instruments. For systolic blood pressure, a one SD genetic increase WHRadjBMI in associated with a 2.1 (95% CI 1.2, 3.0) mm Hg higher systolic blood pressure, or a 0.1 (CI 0.059, 0.15) standard deviation increase in systolic blood pressure. For anthropometric traits, estimates from GIANT were pooled with UK Biobank using inverse variance weighted fixed effects meta-analysis. For lipid, glycemic and renal function traits estimates were derived from genomewide association studies alone (Global Lipids Genetics, Meta-analyses of Glucose and Insulin-related Traits and Chronic Kidney Genetics Consortia, respectively). For blood pressure, estimates were derived from UK Biobank alone. Two-hour glucose refers to measured blood glucose levels two hours after consumption of dissolved glucose in a oral glucose tolerance test. The threshold of statistical significance was p<0.0033 (0.05/15=0.0033). Error bars refer to the 95% confidence interval for each estimate. Size of data marker is inversely proportional to variance of estimate. Abbreviations: PRS, polygenic risk score; OR, odds ratio; SD, standard deviation; WHRadjBMI, waist-to-hip ratio adjusted for body mass index; WHR, waist-to-hip ratio; BMI, body mass index; LDL cholesterol, Low-density lipoprotein cholesterol; HDL cholesterol, High-density lipoprotein cholesterol; HbA1c, hemoglobin a1c; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; waist, waist circumference; hip, hip circumference; beta, beta coefficient. eFigure 4. Association of genetic waist-to-hip ratio adjusted for body mass index with cardiometabolic traits using three instruments, after additional adjustment for body mass index. For systolic blood pressure, a one SD genetic increase WHRadjBMI in associated with a 2.8 (95% CI 1.9, 3.6) mm Hg higher systolic blood pressure, or a 0.14 (CI 0.095, 0.18) standard deviation increase in systolic blood pressure. For anthropometric traits, estimates from GIANT were pooled with UK Biobank using inverse variance weighted fixed effects meta-analysis. For lipid, glycaemic and renal function traits estimates were only derived from genome-wide association studies (Global Lipids Genetics, Meta-analyses of Glucose and Insulin-related Traits and Chronic Kidney Genetics Consortia, respectively). For blood pressure, estimates were only derived from UK Biobank. Two hour glucose refers to measured blood glucose levels two hour after consumption of dissolved glucose. The threshold of significance was p<0.0033 (0.05/15=0.0033). Error bars refer to the 95% confidence interval for each estimate. Size of data marker is inversely proportional to variance of estimate. Abbreviations: PRS, polygenic risk score; OR, odds ratio; SD, standard deviation; WHRadjBMI, waist-to-hip ratio adjusted for body mass index; waist-to-hip ratio, WHR; body mass index, BMI; LDL cholesterol, Low-density lipoprotein cholesterol; HDL cholesterol, High-density lipoprotein cholesterol; HbA1c, hemoglobin a1c; eGFR, estimated glomerular filtration rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; waist, waist circumference; hip, hip circumference; beta, beta coefficient.
eFigure 5. Association of genetically-elevated waist-to-hip ratio adjusted for body mass index (one standard deviation increase) with type 2 diabetes using three instruments with additional adjustment for body mass index. Estimates were independently derived in DIAGRAM using inverse variance weighted regression with adjustment for the association of each variant with body mass index and UK Biobank, using instrumental variables regression adjusting for age, sex, ten principal components of ancestry, array type and body mass index. The threshold of significance was p< 0.025 (0.05/2=0.025). Error bars refer to the 95% confidence interval for each estimate. Size of data marker is inversely proportional to variance of estimate. Abbreviations: PRS, polygenic risk score; OR, odds ratio; SD, standard deviation; SNPs, single nucleotide polymorphisms; WHRadjBMI, waist-to-hip ratio adjusted for body mass index; T2D, type 2 diabetes; DIAGRAM, DIAbetes Genetics Replication And Meta-analysis.
eFigure 10. Association of genetic waist-to-hip ratio adjusted for body mass index with coronary heart disease, before and after adjustment for the mediating association of triglycerides, using the primary 48 SNP polygenic risk score. Estimates were derived from both UK Biobank and CARDIOGRAMplusC4D using inverse variance weighted fixed effects metaanalysis. Error bars refer to the 95% confidence interval for each estimate. Size of data marker is inversely proportional to variance of estimate. Abbreviations: OR, odds ratio; SD, standard deviation; SNPs, single nucleotide polymorphisms; WHRadjBMI, waist-to-hip ratio adjusted for body mass index; CHD, coronary heart disease.
